联合医务中期报告 2025/2026

CONTENTS目錄 2Corporate Information4Financial Highlights6Management Discussion andAnalysis22Corporate Governance Highlights24Other Information37Condensed Consolidated Statementof Profit or Loss38Condensed Consolidated Statementof Comprehensive Income 39Condensed Consolidated Statementof Financial Position41Condensed Consolidated Statementof Changes in Equity42Condensed Consolidated Statementof Cash Flows44Notes to the CondensedConsolidated Interim FinancialStatements68Glossary Corporate Information公司資料 BOARD OF DIRECTORSExecutive DirectorsDr. Sun Yiu Kwong(Chairman) 董事會執行董事 Dr. Sun Man Kin, Michael(Vice Chairman and Co-Chief Executive Officer)Ms. Kwok Cheuk Kwan, Jacquen(Co-Chief Executive Officer)Mr. Tsang On Yip, PatrickBBSDr. Lee Pak Cheung, Patrick 非執行董事2025 Non-executive DirectorsMs. Cheng Chi Man(appointed on 21 November 2025)Dr. Lee Kar Chung, Felix(ceased on 21 November 2025) 112120251121 獨立非執行董事 Independent Non-executive DirectorsMr. Lee Luen Wai, John 2025112120251121 BBS JPMr. Yeung Tak BunBBS JPMrs. Chan Kung Wai Ying, AmyMH(appointed on 21 November 2025)Dr. Li Kwok Tung, DonaldGBS JP(ceased on 21 November 2025) 審核委員會 AUDIT COMMITTEEMr. Lee Luen Wai, JohnBBS JP(Chairman) 2025112120251121 Mr. Yeung Tak BunBBSJPMrs. Chan Kung Wai Ying, AmyMH(appointed on 21 November 2025)Dr. Li Kwok Tung, DonaldGBS JP(ceased on 21 November 2025) 薪酬委員會 REMUNERATION COMMITTEEMr. Lee Luen Wai, JohnBBS JP(Chairman) 202511212025112120251121 (redesignated as Chairman on 21 November 2025)Mr. Tsang On Yip, PatrickBBSMrs. Chan Kung Wai Ying, AmyMH(appointed on21 November 2025)Dr. Li Kwok Tung, DonaldGBS JP(ceased on 21 November 2025) 提名委員會 NOMINATION COMMITTEEDr. Sun Yiu Kwong(Chairman) 2025112120251121 Mr. Lee Luen Wai, JohnBBS JPMs. Kwok Cheuk Kwan, JacquenMr. Yeung Tak BunBBS JPMrs. Chan Kung Wai Ying, AmyMH(appointed on 21 November 2025)Dr. Li Kwok Tung, DonaldGBS JP(ceased on 21 November 2025) 授權代表2026225 AUTHORISED REPRESENTATIVESMs. Kwok Cheuk Kwan, Jacquen Mr. Cheung Chi Wah, Patrick(Note)Ms. Tong Mo Ting(appointed on 25 February 2026) 聯席公司秘書2025121 JOINT COMPANY SECRETARIESMr. Cheung Chi Wah, Patrick(Note) Ms. Tong Mo Ting(appointed on 1 December 2025) 2026225 Note:Mr. Cheung Chi Wah, Patrick resigned as the joint company secretary andceased to act as the authorised representative with effect from 25 February 2026. Corporate Information公司資料 總部及主要營業地點 HEADQUARTERS AND PRINCIPAL PLACEOF BUSINESS27th Floor 7127 Wing On House71 Des Voeux Road CentralHong Kong 註冊辦事處 REGISTERED OFFICECricket Square Cricket SquareHutchins DrivePO Box 2681Grand Cayman KY1-1111Cayman Islands Hutchins DrivePO Box 2681Grand Cayman KY1-1111Cayman Islands 開曼群島主要股份過戶登記處 PRINCIPAL SHARE REGISTRAR AND TRANSFEROFFICE IN THE CAYMAN ISLANDSConyers Trust Company (Cayman) Limited Conyers Trust Company (Cayman) LimitedCricket SquareHutchins DrivePO Box 2681Grand Cayman KY1-1111Cayman Islands Cricket SquareHutchins DrivePO Box 2681Grand Cayman KY1-1111Cayman Islands 香港股份過戶登記分處1617 HONG KONG BRANCH SHARE REGISTRARTricor Investor Services Limited 17/F, Far East Finance Centre16 Harcourt Road, Hong Kong 核數師 AUDITOR KPMGPublic Interested Entity Auditor registered inaccordance with the Accounting andFinancial ReportingCouncil Ordinance 主要往來銀行 PRINCIPAL BANKERSHang Seng Bank LimitedUBS AGChong Hing Bank 財政年度年結日630 FINANCIAL YEAR END30 June 股份代號722 STOCK CODE722 每手買賣單位2,000 BOARD LOT2,000 shares 公司網站www.ump.com.hk COMPANY WEBSITEwww.ump.com.hk Financial Highlights財務摘要 Management Discussion and Analysis管理層討論及分析 概覽 OVERVIEW 2025 Duringthe second half of 2025,Hong Kong’s healthcare sectorcontinued to experience resource pressure and long waiting timesinthe public system,contributing to steady demand for privateoutpatient and diagnostic services. At the same time, rising medicalinsuranceutilisation and higher employee medical premiumssupportedactivity within the private healthcare market.Theseconditionshelped sustain underlying service demand for privateproviders such as the Group, although patient behaviour remainedselective due to economic caution. Forthe six months ended 31 December 2025(“1H FY25/26”),theGroup delivered resilient performance despite a challengingmacroeconomic environment, including high operational costs andintensifying cross-boundary competition. During the period, revenueamounted to HK$367.5 million, representing a modest decline of1.0% year on year, while EBITDA reached HK$45.6 million andprofitfor the period recorded at HK$20.2 million,representedagrowth of 5.0%.Profit attributable to owners of the Companyreported at HK$18.4 million, increased by 2.5% as compared to thatof 1H FY24/25. 202512 312025/26367.51.0%(EBITDA)45.620.25.0%18.42024/252.5% 1.9%2025/26136.734.5%2025/2624.92025/26288.235.1%2025/2610.74.5%2025/2619.12025/262.116.7%2025/2637.7 Segmentperformance was resilient:in Hong Kong and Macau,C o r p o r a t eH e a l t h c a r e S o l u t i o n s r e c o r d e d r